Compare IRWD & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRWD | GPRK |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.6M | 629.3M |
| IPO Year | 2009 | 2009 |
| Metric | IRWD | GPRK |
|---|---|---|
| Price | $3.57 | $10.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 2.0M | 644.3K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $57.95 | $39.45 |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $14.73 | ★ $12.70 |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $0.66 | $5.75 |
| 52 Week High | $5.78 | $11.87 |
| Indicator | IRWD | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 46.17 |
| Support Level | $3.08 | $9.19 |
| Resistance Level | $3.95 | $10.26 |
| Average True Range (ATR) | 0.19 | 0.54 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 67.44 | 12.20 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.